Table 3.
Trials using Anti-EGFR mABs with chemotherapy in chemoresistant mCRC selected by KRAS status.
| Trial (author) | Phase | KRAS | Protocol | Number enrolled | Results | HR (95% CI) | P value | |
|---|---|---|---|---|---|---|---|---|
| PFS | OS | |||||||
| PICCOLO (Seymour et al.) [18] | III | WT WT |
Irinotecan + panitumumab Irinotecan |
Total number of patients = 324 | 10.4 mos. 10.5 mos. |
OS: 0.91 (0.73–1.14) | 0.44 | |
|
| ||||||||
| Study 181 (Sobrero et al.) [19] | III | WT | FOFIRI + panitumumab FOLFIRI |
303 294 |
6.7 mos. 4.9 mos. |
14.5 mos. 12.5 mos. |
PFS: 0.82 (0.69–0.97) OS: 0.92 (0.78–1.10) |
0.023 0.366 |
| MUT | FOFIRI + panitumumab FOLFIRI |
238 248 |
5.3 mos. 5.4 mos. |
11.8 mos. 11.1 mos. |
PFS: 0.95 (0.78–1.14) OS: 0.93 (0.77–1.13) |
0.561 0.482 |
||
WT: wild type, MUT: mutated, PFS: progression free survival, and OS: overall survival.